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AbsTrACT
background and objectives To describe the safety 
and tolerability of intravenous meloxicam compared with 
placebo across all phase II/III clinical trials.
Methods Safety data and opioid use from subjects with 
moderate to severe postoperative pain who received ≥1 
dose of intravenous meloxicam (5–60 mg) or placebo in 
1 of 7 studies (4 phase II; 3 phase III) were pooled. Data 
from intravenous meloxicam 5 mg, 7.5 mg and 15 mg 
groups were combined (low-dose subset).
results A total of 1426 adults (86.6% white; mean 
age: 45.8 years) received ≥1 dose of meloxicam IV; 517 
(77.6% white; mean age: 46.7 years) received placebo. 
The incidence of treatment-emergent adverse events 
(TEAEs) in intravenous meloxicam and placebo-treated 
subjects was 47% and 57%, respectively. The most 
commonly reported TEAEs across treatment groups 
(intravenous meloxicam 5–15 mg, 30 mg, 60 mg and 
placebo, respectively) were nausea (4.3%, 20.8%, 
5.8% and 25.3%), headache (1.5%, 5.6%, 1.6% and 
10.4%), vomiting (2.8%, 4.6%, 1.6% and 7.4%) and 
dizziness (0%, 3.5%, 1.1% and 4.8%). TEAE incidence 
was generally similar in subjects aged >65 years with 
impaired renal function and the general population. 
Similar rates of cardiovascular events were reported 
between treatment groups. One death was reported 
(placebo group; unrelated to study drug). There were 35 
serious adverse events (SAEs); intravenous meloxicam 
15 mg (n=5), intravenous meloxicam 30 mg (n=15) and 
placebo (n=15). The SAEs in meloxicam-treated subjects 
were determined to be unrelated to study medication. Six 
subjects withdrew due to TEAEs, including three treated 
with intravenous meloxicam (rash, localized edema 
and postprocedural pulmonary embolism). In trials 
where opioid use was monitored, meloxicam reduced 
postoperative rescue opioid use.
Conclusions Intravenous meloxicam was generally 
well tolerated in subjects with moderate to severe 
postoperative pain.
Trial registration numbers NCT01436032, 
NCT00945763, NCT01084161, NCT02540265, 
NCT02678286, NCT02675907 and NCT02720692.
InTrOduCTIOn
Meloxicam, a long-acting preferential cycloox-
ygenase (COX)-2 inhibitor, possesses analgesic, 
antipyretic and anti-inflammatory activities.1 2 A 
nanocrystal formulation of meloxicam that can 
be administered by intravenous bolus injection 
was developed for the management of moderate 
to severe pain. Intravenous meloxicam was evalu-
ated in four phase II and three phase III postop-
erative studies, comprising subjects undergoing 
dental impaction surgery,3 open abdominal hyster-
ectomy,4 abdominal laparoscopic surgery,5 bunio-
nectomy,6 7 abdominoplasty8 and major surgery.9 
In these studies, intravenous meloxicam demon-
strated onset of analgesia within 15 min after 
administration with maintenance over a 24-hour 
dosing interval.3 4 6–8 Safety findings from indi-
vidual studies revealed the incidence of adverse 
events was comparable with placebo,3–9 and where 
evaluated, intravenous meloxicam was associated 
with reduced opioid consumption.3 4 6–9 Intrave-
nous meloxicam is an investigational product that 
has not been approved by the US Food and Drug 
Administration.
This pooled analysis was performed to describe 
the safety and tolerability of intravenous meloxicam 
compared with placebo across all phase II/III post-
operative clinical trials. Considering the patho-
physiologic importance of COX in prostanoid 
biosynthesis and subsequent effects on platelet 
aggregation, vasoconstriction and gastrointestinal 
(GI) and renal homeostasis,10 this analysis includes 
examination of safety concerns associated with 
COX inhibition, including bleeding, cardiovascular 
and renal events.
MeThOds
study design and subjects
Data from seven postoperative studies3–9 are included 
in the current analysis (online supplemental digital 
table 1). All subjects who received ≥1 dose of intra-
venous meloxicam or placebo are included in the 
safety set. Data from subjects who received active 
controls (ibuprofen: n=50 [NCT00945763]3; 
morphine: n=47 [NCT01084161]4; and ketorolac: 
n=8 [NCT01436032]5) are not included. Subjects 
(n=56) who switched from placebo in the double-
blind phase to intravenous meloxicam in the open-
label phase of study NCT010841614 were counted 
twice (once in the placebo group and once in the 
intravenous meloxicam group). For subjects (n=21) 
randomized to receive morphine in the double-blind 
phase and then switched to intravenous meloxicam 
in the open-label phase of that same study, data 
were generated, while the subjects on intravenous 
meloxicam are included. In NCT01436032,5 two 
intravenous meloxicam dose groups (7.5 mg and 
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Table 1 Subject disposition, demographics and baseline clinical characteristics in pooled phase II/III clinical trial program
Intravenous meloxicam
Placebo
n=517
5–15 mg
n=327
30 mg
n=910
60 mg
n=189
Overall
n=1426
Completed study, n (%) 504 (97.5) 324 (99.1) 886 (97.4) 189 (100.0) 1399 (98.1)
Reason for discontinuation, n (%)
  Lack of efficacy 0 0 2 (0.2) 0 2 (0.1)
  Adverse event 1 (0.2) 1 (0.3) 0 0 1 (0.1)
  Withdrawal by subject 4 (0.8) 1 (0.3) 11 (1.2) 0 12 (0.8)
  Lost to follow-up 8 (1.5) 0 10 (1.1) 0 10 (0.7)
  Non-compliance 0 1 (0.3) 0 0 1 (0.1)
  Other 0 0 1 (0.1) 0 1 (0.1)
Mean (SD) age, years 46.7 (13.84) 43.0 (11.76) 48.0 (14.59) 40.1 (14.50) 45.8 (14.29)
Gender, % male/female 22.2/77.8 8.0/92.0 30.2/69.8 9.5/90.5 22.4/77.6
Race, n (%)
  White 401 (77.6) 325 (99.4) 737 (81.0) 173 (91.5) 1235 (86.6)
  Black/African-American 94 (18.2) 0 148 (16.3) 10 (5.3) 158 (11.1)
  Asian 9 (1.7) 1 (0.3) 13 (1.4) 1 (0.5) 15 (1.1)
  American Indian/Alaska Native 1 (0.2) 0 1 (0.1) 0 1 (0.1)
  Native Hawaiian/other Pacific Islander 3 (0.6) 0 4 (0.4) 2 (1.1) 6 (0.4)
  Other 6 (1.2) 1 (0.3) 6 (0.7) 2 (1.1) 9 (0.6)
  Multiple 3 (0.6) 0 1 (0.1) 1 (0.5) 2 (0.1)
Mean (SD) body mass index, kg/m2 27.9 (4.33) 25.6 (3.19) 28.4 (4.81) 26.4 (3.42) 27.6 (4.53)
  Positive history for, n (%)
  Hypertension 107 (20.7) 14 (4.3) 232 (25.5) 9 (4.8) 255 (17.9)
  Diabetes 21 (4.1) 2 (0.6) 49 (5.4) 1 (0.5) 52 (3.6)
  Gastrointestinal conditions* 66 (12.8) 4 (1.2) 153 (16.8) 4 (2.1) 161 (11.3)
  Aged >65 years with impaired renal function, n (%)† 35 (6.8) 0 95 (10.4) 1 (0.5) 96 (6.7)
*Prior or concomitant gastrointestinal esophageal reflux disease, ulcer and/or bleeding.
†Impaired renal function defined as a glomerular filtration rate of 60‒89 mL/min/1.73 m2.
SD, standard deviation.
15 mg) received study medication twice daily. Subjects on these 
regimens were grouped by their total daily dose.
evaluations
Safety evaluations included treatment-emergent adverse events 
(TEAEs), vital signs, concomitant medications, clinical labora-
tory parameters, 12-lead ECGs, wound site evaluations, physical 
examination and/or opioid consumption (online supplemental 
digital table 1). All evaluations were made by individual investi-
gators and were not derived from consensus definitions. Investi-
gators determined TEAE severity and the relationship of TEAEs 
with the study drug.
In the phase III studies, investigators provided wound-healing 
satisfaction scores using an 11-point numeric rating scale 
anchored by ‘completely unsatisfied’ (0) and ‘completely satis-
fied’ (10). In addition, investigators rated the symptoms and 
severity of erythema, drainage, edema, induration and hema-
toma using a 5-point Likert scale. Investigators assessed param-
eters rated with a score >0 for clinical significance. If individual 
investigators considered the features under evaluation to be clin-
ically significant, a TEAE was recorded.
Laboratory values and vital signs (heart rate, respiratory rate, 
blood pressure and body temperature) were collected at various 
time points during the postoperative studies. Changes in vital 
signs assessed by the investigator to be clinically meaningful were 
recorded as TEAEs. Because of the differences in data collection 
time points, the clinical laboratory evaluation presented herein 
focuses on the pooled phase III studies.
statistical methods
No missing data imputation was performed. Data from the 
intravenous meloxicam 5 mg, 7.5 mg and 15 mg groups were 
combined (low-dose subset). Descriptive statistics are presented; 
inferential statistics were not produced. Analyses were performed 
using SAS for Windows (V.9.3 or higher).
resulTs
disposition/demographics
The postoperative population included 517 adults who received 
placebo and 1426 adults who received intravenous meloxicam 
(fixed doses, 5–60 mg) for the management of moderate 
to severe postoperative pain (table 1). Most subjects in the 
meloxicam groups (1045/1426; 73.3%) received ≥2 doses, 
including 142/327 (43.4%), 814/910 (89.5%) and 89/189 
(47.1%) subjects in the meloxicam 5–15 mg, 30 mg and 60 mg 
groups, respectively.
Demographics and baseline clinical characteristics are summa-
rized in table 1. Most subjects were white, female and aged<65 
years; most had no history of hypertension, diabetes or GI disor-
ders. A minority (<7%) were aged >65 years and had impaired 
renal function (glomerular filtration rate 60‒89 mL/min/1.73 
m2).
Treatment-emergent adverse events
Fifty-seven percent of subjects in the placebo group and 47% 
of meloxicam-treated subjects experienced ≥1 TEAE (table 2). 
Across all treatment groups (meloxicam 5–15 mg, 30 mg, 60 mg 
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Table 2 Treatment-emergent adverse events (TEAEs) and treatment-
related* TEAEs occurring in ≥3% in any treatment group in pooled 
phase II/III clinical trial program
Intravenous meloxicam
Placebo
n=517
5–15 mg
n=327
30 mg
n=910
60 mg
n=189
Subjects with ≥1 
TEAE, n (%)
296 (57.3) 121 (37.0) 497 (54.6) 59 (31.2)
  Anemia 6 (1.2) 26 (8.0) 19 (2.1) 18 (9.5)
  Constipation 25 (4.8) 8 (2.4) 61 (6.7) 2 (1.1)
  Dizziness 25 (4.8) 0 32 (3.5) 2 (1.1)
  Headache 54 (10.4) 5 (1.5) 51 (5.6) 3 (1.6)
  Insomnia 11 (2.1) 14 (4.3) 13 (1.4) 6 (3.2)
  Ketonuria† 5 (1.0) 23 (7.0) 6 (0.7) 10 (5.3)
  Nausea 131 (25.3) 14 (4.3) 189 (20.8) 11 (5.8)
  Pruritus 15 (2.9) 0 31 (3.4) 2 (1.1)
  Vomiting 38 (7.4) 9 (2.8) 42 (4.6) 3 (1.6)
Treatment-related 
TEAEs
Subjects with ≥1 
treatment-related 
TEAE, n (%)
168 (32.5) 36 (11.0) 221 (24.3) 24 (12.7)
  Headache 29 (5.6) 1 (0.3) 22 (2.4) 3 (1.6)
  Ketonuria† 5 (1.0) 22 (6.7) 6 (0.7) 9 (4.8)
  Nausea 87 (16.8) 3 (0.9) 102 (11.2) 5 (2.6)
  Vomiting 23 (4.4) 3 (0.9) 23 (2.5) 1 (0.5)
*Includes TEAEs possibly, probably and definitely related.
†Ketonuria was reported by one site in study NCT01084161, where the investigator 
was unaccustomed to providing non-steroidal anti-inflammatory drugs for 
postoperative pain. This finding may reflect differences in the timing of resumption 
of adequate oral caloric intake and/or the use of glucose-containing electrolytes.4
Table 3 Treatment-emergent adverse events (TEAEs) occurring in ≥3% in any treatment group in pooled phase II/III clinical trial program by risk 
category*
 
General Population
>65 years with glomerular filtration rate
60‒89 ml/min/1.73 m2 
Placebo
n=482
Intravenous 
meloxicam 5–15 
mg n=327
Intravenous 
meloxicam 30 
mg n=815
Intravenous 
meloxicam 60 
mg n=188
Placebo
n=35
Intravenous 
meloxicam 5–15 
mg n=0
Intravenous 
meloxicam 30 
mg n=95
Intravenous 
meloxicam 60 
mg n=1
Subjects with ≥1 
TEAE, n (%)
269 (55.8) 121 (37.0) 436 (53.5) 58 (30.9) 27 (77.1) 0 61 (64.2) 1 (100.0)
Number of TEAEs 590 198 945 94 76 0 133 5
TEAEs, n (%)
  Nausea 121 (25.1) 14 (4.3) 171 (21.0) 10 (5.3) 10 (28.6) 0 18 (18.9) 1 (100.0)
  Headache 53 (11.0) 5 (1.5) 48 (5.9) 2 (1.1) 1 (2.9) 0 3 (3.2) 1 (100.0)
  Vomiting 35 (7.3) 9 (2.8) 37 (4.5) 3 (1.6) 3 (8.6) 0 5 (5.3) 0
  Constipation 21 (4.4) 8 (2.4) 45 (5.5) 2 (1.1) 4 (11.4) 0 16 (16.8) 0
  Anemia 4 (0.8) 26 (8.0) 14 (1.7) 18 (9.6) 2 (5.7) 0 5 (5.3) 0
  Dizziness 24 (5.0) 0 31 (3.8) 2 (1.1) 1 (2.9) 0 1 (1.1) 0
  Pruritus 13 (2.7) 0 27 (3.3) 2 (1.1) 2 (5.7) 0 4 (4.2) 0
  Insomnia 8 (1.7) 14 (4.3) 11 (1.3) 6 (3.2) 3 (8.6) 0 2 (2.1) 0
  Ketonuria† 5 (1.0) 23 (7.0) 6 (0.7) 10 (5.3) 0 0 0 0
*High risk=subjects who were >65 years with a GFR of 60–89 mL/min/1.73 m2, as calculated using the Modification of Diet in Renal Disease equation.
†Ketonuria was reported by one site in NCT01084161, where the investigator was unaccustomed to providing non-steroidal anti-inflammatory drugs for postoperative pain. This 
finding may reflect differences in the timing of resumption of adequate oral caloric intake and/or the use of glucose-containing electrolytes.4
and placebo, respectively), study investigators assessed TEAEs to 
be mild (23.2%, 44.4%, 20.6% and 45.5%) or moderate (11.6%, 
21.6%, 9.0% and 22.6%) in intensity. The most commonly 
reported TEAEs were nausea, headache, vomiting and dizzi-
ness. Among subjects treated with intravenous meloxicam 30 
mg, constipation occurred at a higher rate among subjects >65 
years with impaired renal function versus the general popula-
tion (table 3). Approximately one-third of subjects in the placebo 
group experienced one or more treatment-related TEAE, as did 
approximately one-fifth of subjects who received any dose of 
intravenous meloxicam (table 2).
deaths, serious adverse events (sAes) and discontinuations
One death was reported in these studies. A 39-year-old place-
bo-treated woman died suddenly 55 days after treatment in 
study NCT02675907.7 Death was attributed to ‘complications 
of the toxic effects of methamphetamine’ and was considered by 
the investigator to be unrelated to study drug.
A total of 35 subjects experienced SAEs during the conduct of 
the clinical studies (placebo: n=15; intravenous meloxicam 15 
mg: n=5; intravenous meloxicam 30 mg: n=15). Investigators 
considered the SAEs experienced by 31 subjects to be unrelated 
to study drug. There were four events (postprocedural hemor-
rhage, postprocedural pulmonary embolism, jejunal stenosis and 
anastomotic ulcer) occurring in three placebo-treated subjects 
that were assessed as possibly related to study drug.
Six subjects had ≥1 TEAE that led to treatment or study 
discontinuation: 3/517 (0.6%) subjects in the placebo group 
(postoperative anemia, drug toxicity, postprocedural hemor-
rhage and postprocedural pulmonary embolism), 1/327 (0.3%) 
subjects in the intravenous meloxicam 5–15 mg group (rash) 
and 2/910 (0.2%) subjects in the intravenous meloxicam 30 mg 
group (localized edema and postprocedural hemorrhage).
Adverse events of special interest (AeOsI)
NSAIDs such as meloxicam have been associated with an 
increased risk of cardiovascular, thrombotic and GI AEs 
(together, AEOSIs).11 Sponsor-defined AEOSIs occurring in >1 
subject are summarized in table 4. Additional details for AEOSI 
that were reported and evaluated by the investigator as unre-
lated to study drug are included in online supplemental digital 
appendix 1.
copyright.
 o
n
 10 July 2019 by guest. Protected by
http://rapm
.bmj.com/
R
egional Anesthesia & Pain M
edicine: first published as 10.1136/rapm
-2018-100184 on 7 February 2019. Downloaded from
 
363Viscusi ER, et al. Reg Anesth Pain Med 2019;44:360–368. doi:10.1136/rapm-2018-100184
Original article
Table 4 Adverse events of special interest (AEOSI) occurring in 
>1 subject in any treatment group in pooled phase II/III clinical trial 
program
Intravenous meloxicam
Placebo
n=517
5–15 mg
n=327
30 mg
n=910
60 mg
n=189
Subjects with ≥1 AEOSI, n (%) 67 (13.0) 41 (12.5) 131 (14.4) 27 (14.3)
  Bleeding* 11 (2.1) 30 (9.2) 33 (3.6) 19 (10.1)
  Cardiovascular 6 (1.2) 0 6 (0.7) 2 (1.1)
  Hepatic 28 (5.4) 8 (2.4) 42 (4.6) 5 (2.6)
  Injection site reactions 6 (1.2) 0 12 (1.3) 0
  Renal 2 (0.4) 0 8 (0.9) 0
  Thrombotic 1 (0.2) 0 4 (0.4) 0
  Wound healing* 17 (3.3) 4 (1.2) 44 (4.8) 3 (1.6)
*Subjects with wound hematoma were counted once in the bleeding and once in 
the wound-healing categories.
Table 5 Treatment-emergent bleeding events occurring in >1 subject 
in any treatment group in pooled phase II/III clinical trial program
Intravenous meloxicam
Placebo
n=517
5–15 mg
n=327
30 mg
n=910
60 mg
n=189
Subjects with ≥1 
bleeding event, n (%)
11 (2.1) 30 (9.2) 33 (3.6) 19 (10.1)
  Anemia 6 (1.2) 26 (8.0) 19 (2.1) 18 (9.5)
  Anemia postoperative 1 (0.2) 0 4 (0.4) 0
  Ecchymosis 0 0 3 (0.3) 0
  Postprocedural 
hematoma
0 2 (0.6) 0 1 (0.5)
  Wound hematoma 0 0 3 (0.3) 0
Bleeding events (anemia, hematoma, hemorrhage or ecchy-
mosis) are summarized in table 5. Anemia events were reported 
for 7/517 (1.4%) subjects who received placebo, 26/327 (8.0%) 
subjects who received intravenous meloxicam 5–15 mg, 23/910 
(2.5%) subjects who received intravenous meloxicam 30 mg and 
18/189 (9.5%) subjects who received intravenous meloxicam 60 
mg. Five subjects (1 [0.2%] placebo and 4 [0.3%] intravenous 
meloxicam 30 mg) required blood transfusions. Among intra-
venous meloxicam-treated subjects, four had hemoglobin and 
hematocrit values below the normal range prior to surgery that 
decreased further after surgery. The report of severe anemia, 
which occurred in a placebo subject, was due to a postproce-
dural hemorrhage (recorded as an SAE). Most subjects with 
anemia were either prescribed medications (eg, ferrous sulfate; 
33/74 [44.6%]) or received no anemia treatment (35/74 
[47.3%]). Anemia was reported in 8/153 (5.2%) subjects with 
a history of GI conditions (esophageal reflux disease, GI ulcer 
and/or bleeding within the GI tract) treated with intravenous 
meloxicam 30 mg. In contrast, anemia was reported in 11/757 
(1.5%) subjects without history of GI conditions treated with 
intravenous meloxicam 30 mg. Among placebo-treated subjects 
with and without history of GI conditions, anemia was reported 
in 1/66 (1.5%) and 5/451 (1.1%) subjects, respectively. In the 
placebo and intravenous meloxicam 30 mg treatment groups, the 
incidence of anemia was higher among subjects who used anti-
thrombotic medications than among those who did not (table 6). 
The increase in rates of anemia associated with concomitant use 
of antithrombotic medications was proportional for subjects in 
the intravenous meloxicam 30 mg and placebo groups compared 
with subjects in the intravenous meloxicam 30 mg and placebo 
groups who did not use these medications.
Across all treatment groups, hematoma events (postproce-
dural or wound) were reported for 2 (0.6%), 3 (0.3%), 1 (0.5%) 
and 0 subjects in the in the intravenous meloxicam 5–15 mg, 30 
mg and 60 mg and placebo groups, respectively. Investigators 
assessed hematoma events as mild (50%) or moderate (50%) in 
severity; each case resolved following intervention (heat therapy, 
phototherapy or incision and drainage). Four events (67%) were 
considered unrelated to study drug; two events (33%, wound 
hematomas in the intravenous meloxicam 30 mg group) were 
considered by the investigator to be possibly related to study 
medication.
Hemorrhagic events (defined as slight bleeding at incision 
site, postoperative incision bleeding, postprocedural hemor-
rhage, rectal bleeding due to constipation and vaginal spotting/
bleeding after gynecological surgery) were reported for 3/517 
(0.6%) subjects who received placebo, 3/910 (0.3%) subjects 
who received intravenous meloxicam 30 mg and 1/189 (0.5%) 
subjects who received intravenous meloxicam 60 mg. The four 
hemorrhagic events in the intravenous meloxicam groups were 
assessed as mild or moderate in severity; three resolved with no 
intervention; one resolved following ligation of an active vessel 
bleed and transfusion of 6 units of packed red cells. Two hemor-
rhagic events in the intravenous meloxicam group were consid-
ered by the investigator to be possibly related to study drug. 
One hemorrhagic event in the placebo group was severe and 
resolved after surgical evacuation of a hematoma and clipping 
of an active vessel bleed and infusion of 3 units of packed red 
cells. The investigator determined this event was possibly related 
to treatment. The other two hemorrhagic events in the placebo 
group were assessed by investigators as being mild in intensity 
and unrelated to treatment.
Cardiovascular events occurred in approximately 1% of 
subjects who received placebo and <1% of subjects who 
received intravenous meloxicam (table 4). Hypertension was the 
most commonly reported cardiovascular event (placebo, 4/517 
[0.8%]; intravenous meloxicam 30 mg, 5/910 [0.5%]). All but 
one of these subjects had a prior medical history of hyperten-
sion. There were four reports of ECG abnormalities. Investiga-
tors assessed the severity of ECG abnormalities to be mild; none 
required treatment. Additional details describing ECG findings 
are provided in online supplemental digital appendix 1. One 
subject treated with placebo had myocardial ischemia secondary 
to coronary artery disease that led to prolonged hospitalization 
and was considered an SAE.
Injection site reactions were reported for approximately 1% 
of subjects (6/517, 1.2%) who received placebo and <1% of 
subjects (12/1426, 0.8%) who received intravenous meloxicam 
(table 4). Injection site reactions were assessed by the investigator 
to be mild (89%) or moderate (11%) in intensity; the reactions 
resolved without additional treatment. The most commonly 
reported injection site event was infusion/injection site pain, 
which occurred in 3/517 (0.6%) subjects who received placebo 
and 5/910 (0.5%) subjects who received intravenous meloxicam 
30 mg. Phlebitis (including injection site phlebitis, vessel punc-
ture site phlebitis and infusion site phlebitis) was reported for 
1/517 (0.2%) subjects in the placebo group and 3/910 (0.3%) 
subjects in the intravenous meloxicam 30 mg group. Other 
events associated with the injection site (infusion site throm-
bosis, injection site erythema, injection site induration, infusion 
site pruritus and injection site infection) were reported for 4/517 
(0.8%) subjects in the placebo group and 4/910 (0.4%) subjects 
in the intravenous meloxicam 30 mg group.
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Table 6 Treatment-emergent adverse events (TEAEs) occurring in ≥3% of subjects in any treatment group overall by history of the use of 
antithrombotic medication in pooled phase II/III clinical trial program
 
use* no use 
Placebo
n=147
Intravenous meloxicam 
5–15 mg
n=192
Intravenous 
meloxicam 30 mg
n=303
Intravenous 
meloxicam 60 mg
n=87
Placebo
n=370
Intravenous 
meloxicam 5–15 
mg n=135
Intravenous 
meloxicam 30 mg
n=607
Intravenous 
meloxicam 60 mg
n=102
Subjects with ≥1 
TEAE, n (%)
94 (63.9) 73 (38.0) 202 (66.7) 35 (40.2) 202 (54.6) 48 (35.6) 295 (48.6) 24 (23.5)
Number of TEAEs 223 112 475 57 443 86 603 42
TEAEs, n (%)
  Nausea 37 (25.2) 2 (1.0) 75 (24.8) 3 (3.4) 94 (25.4) 12 (8.9) 114 (18.8) 8 (7.8)
  Headache 11 (7.5) 1 (0.5) 9 (3.0) 2 (2.3) 43 (11.6) 4 (3.0) 42 (6.9) 1 (1.0)
  Vomiting 14 (9.5) 2 (1.0) 14 (4.6) 0 24 (6.5) 7 (5.2) 28 (4.6) 3 (2.9)
  Constipation 14 (9.5) 6 (3.1) 32 (10.6) 1 (1.1) 11 (3.0) 2 (1.5) 29 (4.8) 1 (1.0)
  Anemia 5 (3.4) 17 (8.9) 16 (5.3) 13 (14.9) 1 (0.3) 9 (6.7) 3 (0.5) 5 (4.9)
  Dizziness 7 (4.8) 0 6 (2.0) 0 18 (4.9) 0 26 (4.3) 2 (2.0)
  Pruritus 6 (4.1) 0 15 (5.0) 0 9 (2.4) 0 16 (2.6) 2 (2.0)
  Insomnia 7 (4.8) 7 (3.6) 9 (3.0) 3 (3.4) 4 (1.1) 7 (5.2) 4 (0.7) 3 (2.9)
  Ketonuria† 4 (2.7) 20 (10.4) 6 (2.0) 10 (11.5) 1 (0.3) 3 (2.2) 0 0
*Within 7 days before the first dose of study drug or during the treatment period.
†Ketonuria was reported by one site in NCT01084161, where the investigator was unaccustomed to providing non-steroidal anti-inflammatory drugs for postoperative pain. This finding may reflect differences in the 
timing of resumption of adequate oral caloric intake and/or the use of glucose-containing electrolytes.4
Hepatic events were reported for approximately 5% of subjects 
in the placebo group and 2%–5% of subjects in the intravenous 
meloxicam groups. Three subjects (placebo, n=1; intravenous 
meloxicam 30 mg, n=2) had severe events (‘liver function test 
abnormal’). Increased transaminases were reported at a higher 
rate in the intravenous meloxicam 30 mg group compared with 
the placebo group (placebo, 0/517 [0%]; intravenous meloxicam 
30 mg, 2/910 [0.2%]).
Renal events were reported for <1% of subjects in the placebo 
and intravenous meloxicam groups (table 4). Investigators 
assessed two renal events in the intravenous meloxicam 30 mg 
group to be of moderate intensity; all other events were assessed 
as mild in intensity. Two subjects experienced an SAE of acute 
renal failure of moderate intensity; for the first subject, the renal 
event occurred on day 18 (the final meloxicam dose was given 
on day 4) and for the other subject, the event occurred on day 
21 (the final meloxicam dose was given on day 3). In both cases, 
investigators considered the events to be unrelated to study 
medication.
Ketonuria was reported by one site in a single study 
(NCT01084161).4 Ketonuria occurred during the double-blind 
and open-label phases of the study and was reported for 5/64 
(7.8%) subjects in the placebo group and for 23/211 (10.9%), 
6/60 (10.0%), and 10/89 (11.2%) subjects in the intravenous 
meloxicam 5–15 mg, 30 mg and 60 mg groups, respectively.
Thrombotic events, including postprocedural pulmonary 
embolism and deep vein thrombosis, were reported for <1% 
of subjects in the placebo and intravenous meloxicam groups 
(table 4). A single subject (0.2%) in the placebo group expe-
rienced a thrombotic event (following abdominoplasty) as 
did four subjects (0.4%) in the intravenous meloxicam 30 mg 
group (following total knee replacement [n=3] and hernia 
repair [n=1]). One subject who received 2 doses of intravenous 
meloxicam 30 mg following total knee replacement surgery had 
a severe postprocedural pulmonary embolism/postoperative 
pulmonary embolus. The investigator assessed the event as unre-
lated to study drug. Of the remaining three events reported by 
subjects in the meloxicam group, none was considered by inves-
tigators to be related to study drug.
Wound healing events across the seven pooled studies 
were reported in <5% of subjects who received placebo or 
intravenous meloxicam (table 4). The rate of wound infection 
was ~1% and consistent across treatment groups (4/517 [0.8%], 
3/327 [0.9%], 7/910 [0.8%] and 1/189 [0.5%] in the placebo, 
intravenous meloxicam 5–15 mg, intravenous meloxicam 
30 mg and intravenous meloxicam 60 mg treatment groups, 
respectively). When ‘cellulitis’ and ‘incision site cellulitis’ were 
analyzed together, the rate of cellulitis associated with the 
wound was <1% in the placebo, intravenous meloxicam 30 
mg and 60 mg groups (3/517 [0.6%], 8/910 [0.9%] and 1/189 
[0.5%], respectively). When abscesses associated with wound 
healing (mesenteric abscess, periumbilical abscess, postoperative 
abscess and abdominal abscess) were analyzed collectively, the 
rate of wound healing abscesses was 2/517 (0.4%) in the placebo 
group and 2/910 (0.2%) in the intravenous meloxicam 30 mg 
group. Wound dehiscence was reported for 2/517 (0.4%), 1/327 
(0.3%), 4/910 (0.4%) and 0/189 (0%) of the placebo, intravenous 
meloxicam 5–15 mg, intravenous meloxicam 30 mg and intrave-
nous meloxicam 60 mg groups, respectively. In the pooled phase 
III studies, investigator satisfaction with wound healing was 
similar between intravenous meloxicam 30 mg and placebo at 
each postoperative evaluation. Mean assessment scores of 9.4/10 
suggest that investigators were consistently satisfied with overall 
wound healing across groups. The incidence of clinically signifi-
cant abnormal wound healing as determined by the investigator 
performing these evaluations was 9/393 (2.3%) for placebo and 
16/748 (2.1%) for intravenous meloxicam 30 mg.
Other information relating to TeAes
Within any of the treatment groups (placebo, intravenous 
meloxicam 5–15 mg, 30 mg and 60 mg), data did not indicate 
a greater incidence of TEAEs overall or in AEOSI, or acute 
reactions by total exposure, risk status, age, sex, race, history 
of select medical conditions (hypertension or diabetes) or the 
use of concomitant medications (antihypertensive or antithrom-
botic). Among subjects with a history of GI conditions, no data 
suggested a greater incidence of TEAEs overall, AEOSI or acute 
reactions apart from anemia discussed above.
Clinically meaningful abnormal laboratory results
Site investigators assessed results from laboratory tests, and any 
measures that were out of the range of normal and evaluated as 
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clinically relevant were subsequently recorded as TEAEs. First, 
a higher percentage of subjects in the intravenous meloxicam 30 
mg group had hemoglobin and hematocrit values that shifted 
from normal at baseline to low during the study compared with 
subjects in the placebo group (hemoglobin: 244/675 [36.1%] 
vs 98/346 [28.3%]; hematocrit: 259/663 [39.1%] vs 112/346 
[32.4%]). Second, the decreases from baseline to the end of 
therapy in hematocrit and hemoglobin were greater in the intra-
venous meloxicam 30 mg group compared with the placebo 
group. At the end of study visit, hematocrit and hemoglobin 
trended toward, but did not reach, baseline in the intravenous 
meloxicam 30 mg group. In the placebo group, hematocrit 
and hemoglobin trends at the end of study were similar to the 
end of therapy. One subject randomized to placebo in study 
NCT02678286 and one subject randomized to intravenous 
meloxicam 30 mg in study NCT02720692 had a report of both 
‘hematocrit decreased’ and ‘hemoglobin decreased’ that were 
deemed clinically significant and reported as an AE.
The only notable differences between the treatment groups 
in the percentage of subjects with potentially clinically signif-
icant chemistry laboratory parameters of special interest was 
a higher percentage of subjects in the intravenous meloxicam 
30 mg group had albumin values that shifted from normal at 
baseline to low during the study compared with subjects in the 
placebo group (96/743 [12.9%] vs 17/390 [4.4%]). Although 
both intravenous meloxicam 30 mg and placebo groups had 
decreases from baseline to the end of treatment in albumin, the 
intravenous meloxicam 30 mg group had a greater shift away 
from baseline. By the end of study visit (approximately 7 days 
after the last dose), albumin approximated baseline in both 
groups. One report of ‘blood albumin decreased’ (mild inten-
sity) in the intravenous meloxicam 30 mg group was deemed 
clinically significant and reported as a TEAE.
There were no notable differences between the treatment 
groups in the percentage of subjects with potentially clinically 
significant coagulation laboratory parameters of special interest 
(activated partial thromboplastin time, prothrombin time and 
prothrombin international normalized ratio). The incidence of 
clinically significant coagulation parameters reported as TEAEs 
was 4/748 (0.5%) and all occurred in the intravenous meloxicam 
30 mg group; investigators assessed the events to be mild or 
moderate in intensity.
Changes in individual laboratory parameters over time were 
evaluated using shift plots. Among the subjects treated with 
intravenous meloxicam 30 mg, no individual laboratory param-
eter was identified as having a clinically meaningful shift.
Changes in vital signs
The incidence of clinically significant vital sign parameters 
reported as TEAEs was low and was generally similar between 
treatment groups in the pooled phase III studies. All events 
occurred only once. The most commonly reported vital sign 
TEAEs in the intravenous meloxicam 30 mg group were hypo-
tension (11/748 [1.5%]) and fever (11/748 [1.5%]). Corre-
sponding rates in the placebo group were 3/527 (2.0%) and 
7/527 (1.8%), respectively.
Opioid consumption
Mean opioid consumption was assessed in the phase III safety 
and tolerability study in subjects undergoing major surgery.9 
Mean opioid consumption in the overall population was signifi-
cantly less in the intravenous meloxicam 30 mg group compared 
with the placebo group in the hour 0‒24, hour 0‒48 and hour 
0‒72 intervals (p<0.05) (table 7). Decreased opioid use among 
subjects treated with intravenous meloxicam 30 mg compared 
with placebo-treated subjects was observed across all subgroups 
(ie, surgery type, risk group and demographic characteristics). In 
the intravenous meloxicam 30 mg treatment group, decreased 
opioid use corresponded to fewer TEAEs commonly associ-
ated with opioid administration during the initial postopera-
tive period (figure 1). Although a statistical evaluation was not 
conducted across the pooled studies, a trend indicating a decrease 
in adverse events commonly associated with opioid administra-
tion such as nausea, vomiting, constipation and pruritus was 
observed (tables 2 and 3).
dIsCussIOn
Intravenous meloxicam was generally well tolerated postop-
eratively in this pooled safety analysis. The most commonly 
reported treatment-related TEAEs across groups were nausea, 
vomiting and headache, all of which occurred with numerically 
lower frequency with intravenous meloxicam versus placebo. 
These findings are consistent with evidence from studies 
conducted with orally and rectally administered meloxicam in 
similar populations,12–15 with no new safety issues identified for 
the intravenous formulation.
In this analysis, TEAE rates were similar across populations, 
including older subjects (>65 years) with impaired renal func-
tion. Among subjects who received intravenous meloxicam 30 
mg, constipation occurred at a higher rate in this subgroup 
compared with younger subjects with normal renal function 
(16.8% vs 5.5%, respectively). No other notable differences in 
TEAEs between subjects in these subgroups who received intra-
venous meloxicam 30 mg were reported. This finding is consis-
tent with data from studies conducted with oral meloxicam, 
which concluded that there was no increased risk of toxicity 
among subjects with mild or moderate renal impairment relative 
to those having normal renal function.16 17
In this pooled analysis, bleeding events occurred in 2.1% of 
subjects in the placebo group and 3.6% of subjects in meloxicam 
treatment groups. The relatively high rates of bleeding events 
in the intravenous meloxicam 5–15 mg and 60 mg groups 
were largely driven by NCT01084161,4 where investigators 
were required to report any hemoglobin value ≤80.0 g/L after 
surgery as a TEAE (irrespective of clinical significance) as well as 
any hemoglobin value after surgery that was between 80.0 g/L 
and 90.9 g/L and had decreased by ≥5.0 g/L from screening. A 
post hoc analysis was performed to further examine the effect 
of treatment on hemoglobin; this analysis revealed no dose-re-
lated trends in the incidence of hemoglobin shifts from normal 
to low, and the difference between the shifts for active treatment 
and placebo was small enough that the effect of treatment on 
hemoglobin was considered similar to that of placebo. Pooled 
data from the phase III studies showed no notable differences 
between the treatment groups in the percentage of subjects with 
potentially clinically significant changes in coagulation param-
eters of special interest (activated partial thromboplastin time, 
prothrombin time and prothrombin international normalized 
ratio). Concomitant antithrombotic use was associated with 
proportional increases in rates of anemia (vs no antithrombotic 
use) in both the placebo and intravenous meloxicam 30 mg treat-
ment groups. The incidence of bleeding events in this analysis is 
consistent with the published literature, including a meta-analysis 
of data from 16 postoperative studies that concluded that single 
doses or short courses of highly selective COX-2 inhibitors in 
the perioperative setting do not increase perioperative bleeding 
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Table 7 Summary of total opioid consumption (mean±SD*) by time interval in subjects undergoing major surgery (NCT02720692)
Interval
All subjects
P value‡
Intravenous meloxicam
(n=537)†
Placebo
(n=183)
0‒24 hours 17.9±22.86 23.3±27.90 0.0025
24‒48 hours§ 8.7±19.20 11.3±21.82 0.0846
48‒72 hours¶ 4.1±16.59 6.2±21.83 0.2725
0‒48 hours 26.3±37.73 34.3±44.08 0.0060
0‒72 hours 28.4±45.49 37.4±55.31 0.0126
During treatment 29.8±58.02 39.0±68.08 0.0531
Orthopedic surgery
P value‡
Other surgery
P value‡
Intravenous meloxicam
(n=282)†
Placebo
(n=96)
Intravenous meloxicam
(n=255)
Placebo
(n=87)
0‒24 hours 22.1±22.75 31.1±30.87 0.0032 13.3±22.14 14.6±21.23 0.4704
24‒48 hours** 11.7±18.67 15.7±23.92 0.0362 5.3±19.25 6.4±18.21 0.7216
48‒72 hours†† 5.3±11.13 8.6±22.80 0.2178 3.1±20.09 4.3±21.07 0.3507
0‒48 hours 33.5±37.05 46.3±46.51 0.0032 18.4±36.96 20.9±37.13 0.5078
0‒72 hours 35.9±40.86 50.0±55.59 0.0037 20.2±48.88 23.5±51.84 0.5308
During treatment 36.8±42.69 50.3±47.7 0.0081 22.1±70.53 26.5±77.95 0.5734
Age <65 years
P value‡
Age ≥65 years
P value‡
Intravenous meloxicam
(n=417)
Placebo
(n=140)
Intravenous 
meloxicam
(n=120)
Placebo
(n=43)
0‒24 hours 17.6±23.66 20.2±24.13 0.0854 19.3±19.86 33.2±36.26 0.0029
24‒48 hours‡‡ 8.4±20.64 10.3±20.54 0.2217 9.6±12.75 14.4±25.47 0.1163
48‒72 hours§§ 4.0±18.03 5.2±18.82 0.7768 4.5±8.90 11.4±33.10 0.0877
0‒48 hours 25.7±40.13 30.2±40.22 0.1118 28.4±27.88 47.6±53.18 0.0030
0‒72 hours 27.8±48.98 33.0±50.38 0.1483 30.4±30.45 51.8±67.68 0.0074
During treatment 29.2±63.01 35.1±67.93 0.2273 32.2±35.73 51.8±67.74 0.0259
>65 years with GFr
60‒89 ml/min/1.73 m2
P value‡
General population
P value‡
Intravenous meloxicam
(n=88)
Placebo
(n=31)
Intravenous meloxicam
(n=449)†
Placebo
(n=152)
0‒24 hours 20.3±21.21 35.5±39.24 0.0047 17.5±23.17 20.8±24.40 0.0682
24‒48 hours¶¶ 10.4±13.19 17.9±29.04 0.0334 8.3±20.13 9.9±19.82 0.3259
48‒72 hours*** 5.6±9.91 13.0±35.24 0.0910 3.8±17.54 5.0±18.59 0.6694
0‒48 hours 30.2±29.29 53.5±59.71 0.0015 25.6±39.16 30.3±39.27 0.1212
0‒72 hours 32.8±32.45 59.4±77.05 0.0037 27.6±47.60 33.0±48.88 0.1577
During treatment 35.2±38.96 59.4±77.12 0.0208 28.8±61.05 34.8±65.59 0.2327
*Intravenous morphine equivalent dose (mg).
†Excluded one subject who had erroneous data that cannot be confirmed.
‡P value from analysis of covariance analysis for treatment group difference.
§n=519 for intravenous meloxicam and n=178 for placebo.
¶n=274 for intravenous meloxicam and n=93 for placebo.
**n=275 and 244 for intravenous meloxicam, and n=93 and 85 for placebo, in orthopedic surgery and other surgery, respectively.
††n=126 and 148 for intravenous meloxicam, and n=41 and 52 for placebo, in orthopedic surgery and other surgery, respectively.
‡‡n=406 and 113 for intravenous meloxicam, and n=135 and 43 for placebo, in subjects <65 years and ≥65 years, respectively.
§§n=219 and 55 for intravenous meloxicam, and n=77 and 16 for placebo, in subjects <65 years and ≥65 years, respectively.
¶¶n=83 and 436 for intravenous meloxicam, and n=31 and 147 for placebo, in subjects >65 years with elevated GFR and the general population, respectively.
***n=42 and 232 for intravenous meloxicam, and n=14 and 79 for placebo, in subjects >65 years with elevated GFR and the general population, respectively.
GFR, glomerular filtration rate; SD, standard deviation.
risk18 as well as data from meloxicam studies demonstrative of 
acceptable GI tolerability (low incidence of GI bleeding).19–21
Shift plots provided information regarding individual labora-
tory parameter changes over time. Although shifts in individual 
parameters were observed, the shifts were generally similar 
between subjects in the intravenous meloxicam 30 mg and 
placebo groups and were potentially attributable to the surgical 
procedures they had undergone.
In the pooled analysis, cardiovascular event rates were similar 
across treatment groups. The studies pooled in this report were 
of limited duration, which may have resulted in few observed 
significant differences in rates of cardiovascular events. Pooled 
data from the phase III studies showed that the incidence of clin-
ically significant ECG parameters reported as TEAEs was low in 
both treatment groups. Data from phase II studies support these 
findings, as do published reports of the cardiovascular safety 
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Figure 1 Treatment-emergent adverse events commonly associated with opioid use (NCT02720692).
of oral meloxicam.12 22 One systematic review of data from 19 
meloxicam studies (observational and randomized, controlled 
trials) concluded that meloxicam increased composite cardiovas-
cular/renal risk slightly but did not elevate myocardial risk.22 A 
2016 review of 40 published studies concluded that short-term 
NSAID use does not increase the risk for adverse cardiovascular, 
GI, renal or respiratory events in most subjects.23
Unexpected ketonuria events were reported across all treat-
ment groups at a single site in NCT01084161,4 where paren-
teral acetaminophen was typically the first line of treatment 
for postoperative pain management rather than NSAIDs. This 
outcome may reflect local practices in the timing of resumption 
of adequate oral caloric intake and/or the use of glucose-con-
taining electrolytes.4
Across the phase II/III clinical trial program, investigators 
followed good clinical practice with regard to reporting AEs. 
There were no uniform consensus definitions for reporting AEs 
across all studies. Difference in surveillance of AEs between 
studies is a limitation of this pooled analysis of safety findings.
In the phase II/III postsurgical study program where opioid 
rescue medication consumption was monitored, intravenous 
meloxicam was often associated with prolonged time to first 
rescue medication use3 4 6 7 and reduced rescue medication 
requirements.3 4 6 8 In both the phase II dental impaction and 
hysterectomy studies, the percentage of subjects using opioid 
medication after surgery was lower in the intravenous meloxicam 
30 mg group compared with the placebo group (37% vs 95% and 
58% vs 93%, respectively).3 4 The administration of intravenous 
meloxicam in the safety and tolerability study (NCT02720692)9 
was associated with reduced opioid consumption (table 7). 
Many expert organizations now recommend strategies such as 
multimodal analgesia, which can include NSAIDs, to reduce 
excessive opioid use.11 24 25
COnClusIOns
The pooled safety data from the phase II/III clinical program 
demonstrate thatintravenous meloxicam was generally well toler-
ated in subjects with moderate to severe postoperative pain as 
indicated by a low incidence of TEAEs that was comparable with 
placebo. In trials where opioid use was monitored, meloxicam 
reduced postoperative rescue opioid use. These findings suggest 
that intravenous meloxicam may represent a useful alternative to 
current postoperative pain management options (non-selective 
NSAIDS and opioid analgesics). Additional studies are needed to 
define the optimal role for intravenous meloxicam in this setting.
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